Companies Dominating the Migraine Drugs Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Eisai Co. Ltd.
- Amneal Pharmaceuticals Inc.
- Abbott Laboratories
- Novarties International AG
- Amgen Inc.
- Teva Pharmaceuticals Industries
- Endo International Plc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of migraine drugs is assessed at USD 6.83 billion.
Migraine Drugs Market size was over USD 6.22 billion in 2024 and is projected to reach USD 25.91 billion by 2037, growing at around 11.6% CAGR during the forecast period i.e., between 2025-2037.
North America industry is expected to dominate majority revenue share by 2037, due to increasing adoption of novel therapies and high prevalence of migraine.
The major players in the market are Pfizer Inc., Eli Lilly and Company, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Abbott Laboratories, Novarties International AG, Amgen Inc., Teva Pharmaceuticals Industries, Endo International Plc., and others.
